• All
  • Important
  • Financial Update
  • Fund Raise
  • Board Meeting
  • Dividend/Bonus
  • JV/Acquisition
  • Investor Meet
  • Insider Trade
  • Pledging
  • Others
    ALPHA TRIBE

    Dr. Reddy's Laboratories Limited — Updates, 21-03-2026: Press Release

    21-03-2026 | 01:59 pm

    Dr. Reddy's launched Obeda®, India's first DCGI-approved generic semaglutide injection for Type 2 Diabetes, marking a Day-1 entry into GLP-1 therapy. Developed in-house, it costs INR 4,200/month and aims for global expansion, strengthening their metabolic disorder portfolio.

    No comments yet. Be the first to comment!

    All announcements from Dr. Reddy's Laboratories Limited